September 2006 Cover
|
 |
Recent in-vitro experiments of the drug PA-457 potentially indicate a new class of HIV maturation inhibitor drugs that could be used to overcome HIV that is resistant to current treatments.
According to Graham Allaway of Panacos Pharmaceuticals, which is developing PA-457, up to 80 percent of HIV patients on treatment show resistance to one or more of their drugs.
In the latest research, PA-457 disrupted the formation of HIV's capsid protein, the conical shield which stores and protects the RNA essential to HIV's replication. The drug binds to the capsid protein at a critical
juncture when normally it is clipped apart from the structural gag protein and assembled into a cone. PA-457 stops the capsid from being clipped, causing the sphere to be permeable, leaving the RNA exposed and HIV unable
to infect human cells.
Previous lab experiments have shown resistant viruses succumb, unable to infect human cells. A small human trial reported last August showed PA-457 reduced HIV by tenfold in the blood within hours. In future trials,
PA-457 will be combined with other HIV drugs and tested in a placebo-controlled trial among 48 patients whose existing treatments are failing.
from Newscientist.com
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
